Tiny study hints at new way to tame PCOS hormones
NCT ID NCT05971849
First seen Nov 05, 2025 · Last updated Jun 22, 2026 · Updated 27 times
Summary
This small study gave 8 women with PCOS a continuous infusion of kisspeptin, a hormone that controls reproduction. Researchers measured changes in luteinizing hormone pulses to see how the reproductive axis responds. The goal was to learn more about the hormone system in PCOS, not to treat symptoms directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYSTIC OVARY SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
kisspeptin 112-121 (a hormone fragment given by IV)
What this could lead to
If successful, this could help researchers understand how kisspeptin might be used to control hormone signals in PCOS, potentially pointing toward future treatments.
What could go wrong
This is a very small, early-phase study with only 8 participants. It measures hormone changes, not health outcomes, so results may not lead to a treatment. Side effects from the infusion are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.